GE HealthCare
(Nasdaq: GEHC)
announced today that it launched its CardioVisio digital tool for helping to treat AFib.
CardioVisio assists clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources. It drives evidence-based clinical decision support directed by up-to-date AFib guidelines.
GE HealthCare plans to showcase the technology at the European Society of Cardiology (ESC) Congress in Amsterdam this week.
By helping clinicians visualize data, CardioVisio can save time and aid decision-making with guideline-directed therapy recommendations. Each automated step includes explainability and traceability. GE HealthCare said this enables the provider to audit and edit the process and output.
Ultimately, the company says, it aims to better meet the needs of each unique AFib patient.
“Existing diagnosis and treatment care models for AFib have been shown to be complex, time-consuming and disconnected with disparate guidelines and poor guideline adherence,” said Eigil Samset, GM, Cardiology Solutions, GE HealthCare. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool that streamlines clinician image interpretation and provides a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
GE HealthCare made CardioVisio for AFib commercially available in the U.S. The company plans to expand availability in the coming months based on additional regional guidelines. It remains unavailable in the European Union as of right now, according to the company.
